Document is current
Any future updates will be listed below
-
Authors
Jouret, Maurine
Viel, Sebastien
Fournier, Benjamin
Benezech, Sarah
Avouac, Jérome
Scherlinger, Marc
Belot, Alexandre
,
Nocturne, Gaetane
Launay, David
Terrier, Benjamin
Bigenwald, Camille
Richez, Christophe
Jourde-Chiche, Noémie
Choquet, Sylvain
Cornec, Divi
Sibilia, Jean
Martin, Thierry
Bitoun, Samuel
Amoura, Zahir
Hermine, Olivier
Mariette, Xavier
Donnadieu, Emmanuel
Bousso, Philippe
Pugnet, Grégory
Decroocq, Justine
Forcade, Edouard
Meyer, Alain
Jorgensen, Christian
Peyrin-Biroulet, Laurent
- License Information
-
More Information
Article History
Received: 31 August 2024
Accepted: 20 April 2025
First Online: 10 May 2025
Declarations
:
: Not applicable.
: Not applicable.
: MJ is a consultant for Novartis. MS is a consultant for Abbvie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Fresenius Kabi, Galapagos, Innate Pharma, Nordic Pharma, Novartis, Sandoz. JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche-Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi, Galapagos, Nordic Pharma. AB is a consultant for Kabi, Roche Chugai, GlaxoSmithKline, AbbVie, Novartis, and Boehringer Ingelheim.
